ZA200503645B - Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds - Google Patents

Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds

Info

Publication number
ZA200503645B
ZA200503645B ZA200500364A ZA200503645A ZA200503645B ZA 200503645 B ZA200503645 B ZA 200503645B ZA 200500364 A ZA200500364 A ZA 200500364A ZA 200503645 A ZA200503645 A ZA 200503645A ZA 200503645 B ZA200503645 B ZA 200503645B
Authority
ZA
South Africa
Prior art keywords
alpha
diseases
combinations
compounds
treatment
Prior art date
Application number
ZA200500364A
Other languages
English (en)
Inventor
Corbett Jeffrey Wayne
Groppi Vincent Edward Jr
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of ZA200503645B publication Critical patent/ZA200503645B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200500364A 2002-12-11 2005-05-06 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds ZA200503645B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43252702P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
ZA200503645B true ZA200503645B (en) 2006-11-29

Family

ID=32507947

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500364A ZA200503645B (en) 2002-12-11 2005-05-06 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds

Country Status (12)

Country Link
US (1) US20050245504A1 (fr)
EP (1) EP1572205A2 (fr)
JP (1) JP2006510662A (fr)
KR (1) KR20050085535A (fr)
CN (1) CN1726033A (fr)
AU (1) AU2003279492A1 (fr)
BR (1) BR0317110A (fr)
CA (1) CA2508004A1 (fr)
MX (1) MXPA05005666A (fr)
PL (1) PL377777A1 (fr)
WO (1) WO2004052348A2 (fr)
ZA (1) ZA200503645B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CN1918131B (zh) 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
AR049401A1 (es) * 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
CA2589102C (fr) 2004-11-02 2013-08-13 Northwestern University Composes de pyridazine et methodes d'utilisation des composes pour traiter les maladies inflammatoires
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CA2650711A1 (fr) 2006-04-28 2007-11-08 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US20100233156A1 (en) * 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
CA2789014C (fr) 2010-02-09 2019-01-15 Michela Gallagher Procedes et compositions pour ameliorer la fonction cognitive
RS54742B1 (sr) 2010-05-17 2016-10-31 Forum Pharmaceuticals Inc Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata
CN103260619A (zh) * 2010-07-26 2013-08-21 英维沃医药有限公司 利用某些α-7烟酸受体激动剂与乙酰胆碱酯酶抑制剂的组合治疗认知障碍
WO2013019901A2 (fr) * 2011-08-02 2013-02-07 Buck Institute For Research On Aging Esters de tropinol et composés apparentés destinés à favoriser le traitement normal de l'app
EP2763676B1 (fr) * 2011-10-03 2019-12-25 The University of Utah Research Foundation Application d'antagonistes du récepteur 5-ht6 dans l'atténuation des déficits cognitifs liés au syndrome de down
WO2013169646A1 (fr) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (fr) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam pour améliorer la fonction cognitive
EP3233087B1 (fr) * 2014-12-16 2019-10-02 Axovant Sciences GmbH Composés amide de quinuclidine à substituants géminal, en tant qu'agonistes des récepteurs nicotiniques de l'acétylcholine 7
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
MX2018000916A (es) 2015-07-22 2018-09-05 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de rsv.
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
EP3897670A4 (fr) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
KR20220101083A (ko) 2019-10-04 2022-07-19 이난타 파마슈티칼스, 인코포레이티드 항바이러스 헤테로사이클릭 화합물
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2022086840A1 (fr) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Composés hétérocycliques en tant qu'agents antiviraux
CN112625057B (zh) * 2020-12-25 2022-12-09 山东金城柯瑞化学有限公司 3-羟基-4-((三甲基甲硅烷基)乙炔基)苯甲酸甲酯的合成方法
JP2024507561A (ja) * 2021-02-26 2024-02-20 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス複素環式化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6500840B2 (en) * 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (fr) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
MXPA03010733A (es) * 2001-05-22 2004-07-01 Upjohn Co Compuestos de etilamina aza-hidroxilados.
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
CN1726033A (zh) 2006-01-25
KR20050085535A (ko) 2005-08-29
BR0317110A (pt) 2005-10-25
JP2006510662A (ja) 2006-03-30
WO2004052348A3 (fr) 2004-10-21
US20050245504A1 (en) 2005-11-03
PL377777A1 (pl) 2006-02-20
EP1572205A2 (fr) 2005-09-14
CA2508004A1 (fr) 2004-06-24
MXPA05005666A (es) 2005-07-26
WO2004052348A2 (fr) 2004-06-24
AU2003279492A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
ZA200503645B (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
EP1416961A4 (fr) Composition et procede pour le traitement d'une maladie
EP1539210A4 (fr) Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1570839A4 (fr) Composition pour une preparation destinee a un usage externe sur la peau, et methode d'utilisation s'y rapportant
EP1487446A4 (fr) Heterocycles bicycliques pour le traitement des diabetes et d'autres maladies
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
AU2003268295A8 (en) "diagnosis and treatment of infertility"
GB0212405D0 (en) Composition and its therapeutic use
EP1575497A4 (fr) Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
GB0207410D0 (en) Compounds and their therapeutic use
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1545287A4 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
EP1539100A4 (fr) Compositions et methodes pour le traitement de troubles cutanes
AU2003282593A8 (en) Polyphenolamine composition and method of use
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use
EP1483407A4 (fr) Methodes therapeutiques et diagnostiques
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders